Skip to content

menu

Rothwell, Figg, Ernst & Manbeck, P.C. logo
HomeAboutContact
Rothwell Figg's

Biosimilars Law Bulletin

RegulatoryLegalNews

RFEM’s Biosimilars Inter Partes Review (IPR) Dashboard

RF-Generic-Logo-sm
By Nicole Gifford & Benjamin R. Holt on November 14, 2018
Posted in Legal

RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar products.

Tags: abatacept, adalimumab, Avastin®, bevacizumab, Enbrel®, etanercept, Featured, Herceptin®, Humira®, IPR, Legal, Natalizumab, Neulasta®, News, Orencia®, pegfilgrastim, PTAB, Rituxan®, Rituximab, trastuzumab, Tysabri®, USPTO
Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Related Posts
Supreme Court panoramic with text Equal Justice Under Law
Will the Supreme Court Take the Bait? CVSG Issued and Other Updates in the Amgen v. Sanofi Case
May 3, 2022
Scientific analysis
Humira's End of Reign
March 18, 2022
Secret, mute, silence, quiet vector icon illustration
Is Silence Disclosure?
February 8, 2022

Blog Editors

Photo of E. Anthony FiggE. Anthony FiggMember
Photo of Joseph A. HyndsJoseph A. HyndsMember
Photo of Jennifer P. NockJennifer P. NockMember
Photo of Aydin H. HarstonAydin H. HarstonMember

About this Blog

Authored and edited by attorneys in Rothwell Figg’s Biologics and Biosimilars Group, Rothwell Figg’s Biosimilars Law Bulletin provides updates, articles, and analyses regarding regulatory issues, legal decisions, and other news related to biologics and biosimilars under the Biologics Price Competition and Innovation Act (BPCIA).

Read More....

Stay Connected

RSS LinkedIn Twitter Facebook
Subscribe to this blog

Topics

Archives

Blog Authors Show/Hide

  • D. Lawson Allen
  • Nicole M. DeAbrantes
  • Kathleen DiNapoli
  • Rachel M. Echols
  • Aydin H. Harston
  • Monica Chin Kitts
  • Alvin Lee
  • Malissa Magiera
  • Jennifer P. Nock
  • Andrew J. Storaska
  • Anjali Jenna (AJ) Teigen
  • Sheena Wang
  • Richard E. Waterman
  • Caitlin M. Wilmot
  • Xiaoban Xin

Recent Posts

  • Senators Urge Regulators to Block and Clear Patent Thickets
  • Purple Book Update – Regeneron’s EYLEA (aflibercept)
  • Will the Supreme Court Take the Bait? CVSG Issued and Other Updates in the Amgen v. Sanofi Case
  • Rehearing Denied in Federal Circuit’s Ruling Against Tecfidera® Patent for Lack of Written Description
  • Regeneron Disclaims an Aflibercept Formulation Patent in Response to Celltrion PGR

Rothwell Figg Blogs

  • Healthcare Marketing Law
  • Privacy Zone
  • PTAB Law Blog
  • RF EMerge
  • Trademark Opposition Lawyer
Rothwell, Figg, Ernst & Manbeck, P.C.
New York
80 South Highland Ave
Ossining, NY 10562
914.941.5668
info@rfem.com
Washington, DC
607 14th St. NW
Suite 800
Washington, DC 20005
202.783.6040
info@rfem.com
Boston
One Boston Place
Suite 2600
Boston, MA 02108
617.312.3101
info@rfem.com
RSS LinkedIn Twitter Facebook
Privacy PolicyDisclaimer

About Our Firm

To learn more about our firm and other practice areas, visit www.rfem.com.

Copyright © 2022, Rothwell, Figg, Ernst & Manbeck, P.C.. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo